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Human kallikrein gene delivery protects against gentamycin-induced
nephrotoxicity in rats. The tissue kallikrein-kinin system has been shown
to play important roles in cardiovascular and renal function. The aim of
this study was to investigate potential protective effects of kallikrein gene
delivery in gentamycin-induced nephrotoxicity. Rats were injected subcu-
taneously with gentamycin daily for 10 to 14 days. Adenovirus, Ad.CMV-
cHK carrying the human tissue kallikrein gene or Ad.CMV-LacZ carrying
the b-galactosidase gene under the control of the cytomegalovirus pro-
moter, were delivered intravenously on the first day of gentamycin
administration. The expression of human tissue kallikrein mRNA was
identified in the kidney, aorta, heart and liver and immunoreactive human
kallikrein levels were measured in the serum and urine of rats receiving
kallikrein gene delivery. Adenovirus-mediated kallikrein gene delivery
significantly increased the renal blood flow, glomerular filtration rates, and
urine flow while it attenuated renal tubular damage, cellular necrosis,
lumenal protein casts and reduced ventricular weight and cardiomyocyte
size. Kallikrein gene delivery caused a decrease in blood urea nitrogen
levels and increases in urinary kinin and nitrite/nitrate levels. This study
shows that kallikrein gene delivery exhibits protection against gentamycin-
induced nephrotoxicity, and raises the potential for kallikrein gene
therapy to treat drug-induced renal diseases.
Gentamycin is an aminoglycoside antibiotic commonly used in
treating life-threatening gram negative bacterial infections. How-
ever, 30% of the patients treated with gentamycin for more than
seven days show some sign of nephrotoxicity [1], and serious
complications resulting from gentamycin-induced nephrotoxicity
are a limiting factor for its clinical usage [2]. Previous studies
suggested that gentamycin causes lysosomal phospholipidosis by
inhibiting the activity of phospholipase A and C, and thus induces
cell membrane damage in the renal proximal tubules [3–5]. A
potential therapeutic approach to protect or reverse the antibiot-
ic’s effects on renal tubular damage would have significant clinical
applications. Gentamycin administration into rats provided an
excellent model of acute renal failure for studying therapeutic
potential in preventing the side effects of acute renal failure
pathogenesis in humans.
Tissue kallikrein (E.C. 3.4.21.35) is a serine proteinase that is
capable of cleaving low molecular weight kininogen to produce
the vasoactive kinin peptide [6, 7]. The binding of kinins with
bradykinin B2 receptors produces a broad spectrum of biological
effects, including smooth muscle contraction and relaxation,
increase in vascular permeability, vasodilation, electrolyte and
glucose transport, and pain [7]. Extensive clinical studies showed
that urinary kallikrein levels are inversely correlated with blood
pressure [8]. Reduced urinary kallikrein levels have also been
observed in a number of genetically hypertensive rats [9–12].
Since urinary kallikrein originates from the kidney, the correlation
between high blood pressure and reduced urinary kallikrein levels
suggests participation of tissue kallikrein in renal function and
blood pressure homeostasis. Long-term infusion of purified rat
tissue kallikrein via a minipump has been shown to attenuate
glomerular sclerosis without affecting the blood pressure of
Dahl-salt sensitive rats fed on a high salt diet [13]. This finding
indicates that a continuous supply of tissue kallikrein might
provide protective effects on salt-induced renal injury. This find-
ing is consistent with our recent studies that adenovirus-mediated
gene delivery of human tissue kallikrein alleviated salt-induced
renal damage in Dahl-salt sensitive rats fed a high salt diet [14]
and enhanced renal function in two-kidney, one-clip Goldblatt
hypertensive rats [15]. Together, these results suggest beneficial
effects of tissue kallikrein in renal function.
In this study, we evaluated the protective effects of tissue
kallikrein gene delivery in the rat model of gentamycin-induced
nephroxicity. Our studies showed that systemic delivery of the
human tissue kallikrein gene in an adenovirus vector to gentamy-
cin nephrotoxic rats led to increased renal function and attenua-
tion of renal damage. These findings suggest the potential of
applying kallikrein gene therapy approaches in treating drug-
induced renal diseases.
METHODS
Preparation of replication-deficient adenoviral vector Ad.CMV-
cHK
Plasmid CMV-cHK was constructed as previously described
[16], in which the expression of human tissue kallikrein cDNA was
under the control of the cytomegalovirus enhancer/promoter and
was followed by the bovine growth hormone gene polyadenylation
signal sequence. Plasmid pAd.CMV-cHK was constructed by
inserting the CMV-cHK-polyA transcription unit into the adeno-
viral shuttle vector pAdLink.1 at an EcoRV site. The pAd.CMV-
cHK plasmid DNA was purified using a Qiagen plasmid DNA kit
(Qiagen, Chatsworth, CA, USA) and the purified DNA was sent
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to the Institute for Human Gene Therapy, Wistar Institute
(Philadelphia, PA, USA) for generating adenovirus Ad.CMV-
cHK harboring the CMV-cHK-polyA transcription unit. Adeno-
virus harboring the LacZ gene under the control of the cytomeg-
alovirus enhancer/promoter (Ad.CMV-LacZ) was obtained from
the Institute for Human Gene Therapy.
Animal treatment
Sprague-Dawley rats (male, 200 to 220 g body wt; Harlan
Sprague Dawley, Inc., Indianapolis, IN, USA) were used in this
experiment. The rats were housed at a constant room temperature
with a 12 hour light/12 hour dark cycle and had free access to tap
water and rat chow. The rats were divided at random into four
groups with six animals in each group. The first group was injected
subcutaneously with 0.9% NaCl (2 ml/g body wt). The other three
groups received gentamycin sulfate (Sigma Chemical, St. Louis,
MO, USA) subcutaneously at a dose of 80 mg/kg in saline
solution. The injection was carried out for 10 consecutive days.
The third group was injected with adenovirus Ad.CMV-LacZ and
the fourth group with adenovirus Ad.CMV-cHK (4.0 3 1010
plaque-forming units) via the tail vein on the first day of genta-
mycin treatment.
Blood pressure measurement
Systolic blood pressure was measured with a photoelectric tail
cuff device (Natsume Co., Tokyo, Japan). This device requires
minimal warming of the rats (usually , 20 min) prior to blood
pressure determination and a brief period of restraint in a plastic
cage. An average of ten readings was taken for each animal. Heart
rate were measured at the same day of blood pressure measure-
ment. Body weights were recorded daily.
RT-PCR Southern blot analysis of human tissue kallikrein
mRNA
Total RNA was extracted from fresh rat tissues by TRIZOL
(Gibco BRL, Grand Island, NY, USA). The reaction mixture for
reverse transcription (RT) contained 1 mg of total RNA from
several tissues, 20 pmol of the 39 primer (59-GCCACAAGG-
GACGTAGC-39 located on the fifth exon of the human tissue
kallikrein gene), 20 nmol of dNTP, 0.2 mmol of DTT, 4 ml of 5 3
reverse transcription buffer (250 mM Tris-HCl, pH 8.3, 375 mM
KCl, 15 mM MgCl2) and 200 U of Maloney murine leukemia virus
reverse transcriptase (Gibco BRL) in a total volume of 20 ml. The
reverse transcription reaction mixture was incubated at 37°C for
one hour to synthesize the first strand of cDNA. Twenty pico-
moles of 59 primer (59-CATTTCAGCACTTTCCA-39 located on
the second exon of the human tissue kallikrein gene), 5 ml of 10 3
PCR buffer, and 0.5 U of Taq DNA polymerase were added to the
RT mixture to a total volume of 50 ml followed by 30 cycles of
hot-start polymerase chain reaction (PCR; 94°C, 1 min; 55°C, 1
min; 72°C, 1 min) with Ampliwax (Perkin-Elmer Cetus Instru-
ments, Norwalk, CT, USA) in a thermal cycler. Thirty microliters
of RT-PCR products were subjected to a Southern blot analysis.
A specific oligonucleotide (59-ACGACCTTCACAGCGTC-39 lo-
cated on the third exon of the human tissue kallikrein gene) was
used as a probe for hybridization at 42°C. The membrane was
washed in 6 3 SSC twice at room temperature and exposed to
X-Omat film at 280°C (Eastman Kodak Co., Rochester, NY,
USA).
Serum and urine collection
At various time points after injection of adenoviral vectors,
serum was collected and measured for human tissue kallikrein
levels. The 24-hour urine samples were collected on day 7 using
metabolic cages. To eliminate the contamination of food particles
in urine samples, rats only received tap water during the collection
period. Urine samples were collected and centrifuged at 1000 3 g
to remove particles. The volume was measured and the superna-
tant was used for further analysis. Blood urea nitrogen was
measured on day 10 by a modified urease-indophenol method
[17].
Enzyme-linked immunosorbent assay for human tissue
kallikrein
The level of human tissue kallikrein in serum was determined
by enzyme-linked immunosorbent assay (ELISA) [18]. Briefly, a
96-well microplate was coated with human tissue kallikrein im-
munoglobulin G (1 mg/ml in PBS, 100 ml/well) at 4°C overnight.
The plate was blocked with 200 ml of PBS containing 1% bovine
serum albumin at 37°C for one hour and washed three times with
PBS containing 0.1% Tween-20. One hundred microliters of
human tissue kallikrein standard (0.4 ng/ml to 25 ng/ml) or
samples were added into each well. The plate was incubated at
37°C for 1.5 hours and washed. Biotin-labeled human tissue
kallikrein immunoglobulin G was added to each well at a concen-
tration of 1 mg/ml in a total volume of 100 ml. The plate was
incubated at 37°C for one hour and washed. Avidin-peroxidase at
a concentration of 1 mg/ml and 100 ml/well was added and
incubated with the substrate solution (3 mg of 2,29-azinobis
(3-ethylbenzthiazoline) sulfuric acid, 10 ml of 3% H2O2 in 10 ml
of 0.1 M citric acid, pH 4.3). After 30 minutes, the plate was read
on an ELISA plate reader at 405 nm for absorbance.
Urinary nitrite/nitrate and kinin measurements
Urine samples were sent to the New York Medical College for
measurements of nitrite/nitrate (NOx) content. Urinary NOx
contents were measured by a colorimetric assay based on the
Griess reaction [19]. Urinary kinin levels were measured by a
direct kinin radioimmunoassay as previously described [20].
Measurement of urine flow rate, glomerular filtration rate and
renal blood flow
Rats were anesthetized with pentobarbital (50 mg/kg, i.p.) and
placed on a heating pad for maintenance of body temperature at
37°C. After tracheotomy, a cannula was placed in the jugular vein
for infusion of fluids and drugs. A cannula was placed in the right
femoral artery for the measurement of blood pressure and for
blood sampling. The bladder was cannulated to allow urine
collection from the right kidney. The left kidney was exposed by a
flank incision, freed of perirenal tissue, placed in a Lucite cup, and
bathed in 0.9% NaCl and then the ureter was cannulated.
Hydropenic preparations were maintained by an intravenous
injection of 1.2 ml of 0.9% NaCl containing 10% polyfructosan
(Inutest, Laevosan, Linz, Austria) and 2% para-aminohippuric
acid (PAH; Merck Sharp & Dohme, West Point, PA, USA) via
the cannula in the jugular vein during the experimental period.
Forty-five minutes was allowed for the preparation to reach a
steady state. Timed urine collections were obtained, with blood
(0.6 ml) collected between clearance periods. For maintenance of
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hematocrit, red blood cells from each blood sample were recon-
stituted to the same volume with 0.9% NaCl and reinjected
through the arterial cannula. At the end of each experiment,
kidneys were excised, blotted, and weighed. Urine volume was
determined gravimetrically. Polyfructosan and PAH concentra-
tions were determined by modified anthrone and colorimetric
methods, respectively [21]. Glomerular filtration rate (GFR) and
renal plasma flow (RPF) were determined from the clearance of
polyfructosan and PAH, respectively. Renal blood flow (RBF)
was calculated from RPF and hematocrit. Clearance data were
normalized to kidney weight.
Morphological and histological investigation
Rats were anesthesized with pentobarbital (50 mg/kg body wt)
and hearts and kidneys were removed, cleaned, washed in saline,
blotted and weighed. The right ventricular free wall was carefully
dissected from the left. The intraventricular septum was thus
included in the left ventricular weight. Sections of the kidney and
heart were preserved in 4% buffered formaldehyde solution and
embedded in paraffin. Five micrometer-thick sections were cut
and stained with hematoxylin-eosin and/or periodic acid-Schiff
(PAS), and analyzed microscopically and morphometrically. For
assessing the hypertrophy of myocardial cells, the shortest trans-
verse diameter of fibers sectioned through the nuclei was mea-
sured with an ocular with an engraved measuring scale. An ocular
micrometer was calibrated against a stage micrometer, and con-
version factors were calculated for low (34 objective) and high
(345 objective) magnifications. The mean diameter of 400 car-
diomycytes in each group was measured with a calibrated eyepiece
at a magnification factor of 3450. All sections were evaluated by
independent personnel without the prior knowledge of the group
in which the rats belonged.
Statistical analysis
Group data are expressed as mean 6 SEM. Statistical analysis
was performed by ANOVA (analysis of variance) and Student’s
t-test. Differences were considered significant at a value of P ,
0.05.
RESULTS
Expression of human tissue kallikrein mRNA in rats receiving
kallikrein gene delivery
Human tissue kallikrein mRNA in tissues of rats receiving gene
delivery was analyzed by RT-PCR followed by Southern blot
analysis using specific oligonucleotide probes for human tissue
kallikrein. Total RNAs were prepared from heart, liver, kidney,
and aorta four days after intravenous injection of the adenoviral
Ad.CMV-cHK carrying the human tissue kallikrein gene or the
control adenovirus Ad.CMV-LacZ carrying the b-galactosidase
gene under the control of the cytomegalovirus (CMV) promoter.
Human tissue kallikrein mRNA was detected mainly in the liver
and kidney and to a lesser extent in the heart and aorta (Fig. 1,
upper panel, left). The expression of human tissue kallikrein
mRNA was not detected in control rats receiving Ad.CMV-LacZ
(Fig. 1, upper panel, right). Similar levels of b-actin mRNA were
detected in tissues of rats injected with Ad.CMV-cHK or
Ad.CMV-LacZ, indicating the integrity of RNA in these samples
(Fig. 1, lower panel). The results show that human tissue kal-
likrein is expressed in rat tissues relevant to cardiovascular and
renal function following gene transfer.
Time course of immunoreactive human tissue kallikrein in rats
receiving kallikrein gene delivery
Immunoreactive human tissue kallikrein levels in rats receiving
kallikrein gene delivery were measured by an ELISA specific for
human tissue kallikrein. Human tissue kallikrein in serum and
urine of rats receiving gene delivery displayed parallelism to the
human tissue kallikrein standard, indicating their immunological
identity (Fig. 2). No immunoreactive human tissue kallikrein was
detected in serum or urine of control rats receiving adenovirus
Ad.CMV-LacZ (Fig. 2). Following intravenous injection of ade-
novirus Ad.CMV-cHK, serum levels of immunoreactive human
tissue kallikrein increased rapidly, reaching the highest level of
744 6 107 ng/ml (mean 6 SEM, N 5 5) at three days post-gene
delivery and declining gradually (Fig. 3).
Fig. 1. Expression of human kallikrein mRNA
in Sprague-Dawley rats after human kallikrein
gene delivery. The rats were sacrificed 4 days
post-injection and 1 mg of RNA was used for
RT-PCR. Southern blot analysis of the RT-
PCR products was carried out. Human
kallikrein mRNA in rat tissues was amplified by
a set of specific oligonucleotides for human
tissue kallikrein which yielded a partial cDNA
(503 bp) product as shown in the upper panel.
Rat b-actin mRNA in rat tissues was amplified
by a set of specific oligonucleotides which
yielded a 500 bp product as shown in the lower
panel. RNAs from heart, liver, kidney and aorta
of rats receiving Ad.CMV-cHK of Ad.CMV-
LacZ are indicated.
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Decreased blood urea nitrogen in rats receiving kallikrein gene
delivery
Figure 4 shows blood urea nitrogen (BUN) levels in rats 10 days
post-gene delivery. The gentamycin-treated group with or without
Ad.CMV-LacZ gene delivery had four times higher levels of BUN
than the control group given saline (85.4 6 0.6 and 85.4 6 1.2 vs.
19.0 6 0.3 mg/100 ml serum, N 5 4, P , 0.01). The BUN levels
(28.6 6 0.3 mg/100 ml serum, N 5 4) in rats injected with
gentamycin and Ad.CMV-cHK were markedly reduced to those
of control rats injected with only saline (19.0 6 0.3 mg/100 ml
serum).
Effects of kallikrein gene delivery on the physiological
parameters in gentamycin-induced nephrotoxic rats
Table 1 shows the results of physiological analysis of gentamy-
cin-treated rats seven days after gene delivery. There were no
apparent changes in the body wt, blood pressure, heart rate, urine
volume and water intake among the groups with gentamycin
administration or between rats injected with Ad.CMV-LacZ
versus Ad.CMV-cHK. However, urinary kinin levels increased
threefold after kallikrein gene delivery as compared to the
Ad.CMV-LacZ group (87.8 6 21.4 vs. 29.5 6 4.6 ng/100 g body
wt/day, N 5 6, P , 0.01) in gentamycin-treated rats. Urinary
human tissue kallikrein (4.2 6 0.9 mg/100 g body wt/day, N 5 6)
could be detected in rats seven days post-kallikrein gene delivery
but not in rats injected with Ad.CMV-LacZ.
Effects of kallikrein gene delivery on the renal function in
gentamycin nephrotoxic rats
Table 2 shows the results of renal hemodynamics and renal
function in gentamycin nephrotoxic rats 10 days after gene
delivery. The kidney weight of rats treated with gentamycin with
or without Ad.CMV-LacZ and gentamycin with Ad.CMV-cHK
were significantly higher than those of control rats injected with
saline. Body weight of these gentamycin-treated groups were
significantly lower than the control group. Kallikrein gene delivery
caused a significant increase in urine flow (18.5 6 0.4 ml/min/g
kidney wt, N 5 4, P , 0.01) as compared to the group receiving
control adenovirus Ad.CMV-LacZ (5.0 6 0.2 ml/min/g kidney wt,
N 5 4), gentamycin alone (4.4 6 0.3 ml/min/g kidney wt, N 5 4)
or control rats injected with saline (5.7 6 0.4 ml/min/g kidney wt,
N 5 4). Similarly, GFR (3.07 6 0.07 vs. 0.83 6 0.04 ml/min/g
kidney wt, N 5 4, P , 0.01) and RBF (32.0 6 2.1 vs. 9.2 6 0.6
ml/min/g kidney wt, N 5 4, P , 0.01) were significantly increased
in rats injected with Ad.CMV-cHK compared to rats receiving the
control adenovirus Ad.CMV-LacZ. Mean arterial pressure and
hematocrit were measured during the renal function study and
there were no significant differences among the groups.
Fig. 2. Enzyme-linked immunosorbent assay of recombinant human
tissue kallikrein in the serum and urine of Sprague-Dawley rats receiving
adenoviral vectors Ad.CMV-cHK and Ad.CMV-LacZ. The standard curve
of human tissue kallikrein (E), ranging from 0.4 to 12.5 ng/ml, is shown
along with serial dilutions of rat serum (F; Ad.CMV-cHK) which was
obtained at three days and urine (; Ad.CMV-cHK) at seven days after
kallikrein gene delivery. Human tissue kallikrein was not detected in the
serum of control rats receiving Ad.CMV-LacZ adenovirus ().
Fig. 3. Time course of human tissue kallikrein levels in gentamicin-
treated rat serum after adenovirus-mediated gene delivery. Human tissue
kallikrein was not detected in the Ad.CMV-LacZ group. The immunore-
active human tissue kallikrein in the serum was highest three days after
gene delivery. Data are expressed as mean 6 SEM (N 5 5).
Fig. 4. Blood urea nitrogen in rats receiving kallikrein gene delivery.
Data are expressed as mean 6 SEM (N 5 4). *P , 0.01 versus the
gentamycin and Ad.CMV-LacZ group.
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Protective effects of kallikrein gene delivery on cardiac
hypertrophy in gentamycin nephrotoxic rats
As shown in Figure 5, the mean left ventricular weight of the
gentamycin-treated rats with or without adenovirus, Ad.CMV-
LacZ (0.34 6 0.02 g/100 g body wt, and 0.32 6 0.03 g/100 g body
wt, N 5 4) increased significantly as compared to that of rats
injected with saline alone (0.26 6 0.01 g/100 g body wt, N 5 4, P ,
0.01) and kallikrein gene delivery significantly reduced left ven-
tricular weights (0.27 6 0.01 g/100 g body wt, N 5 4, P , 0.01) to
those of control rats. Similarly, the mean cardiomyocyte diameter
of the gentamycin-treated group with or without adenovirus
Ad.CMV-LacZ (13.9 6 0.1 mm, N 5 400 and 13.8 6 0.3 mm, N 5
400) increased significantly as compared to that of rats injected
with saline alone (11.7 6 0.5 mm, N 5 400, P , 0.01), and
kallikrein gene delivery significantly reduced cardiomyocyte size
as compared with rats receiving Ad.CMV-LacZ (11.9 6 0.2 vs.
13.9 6 0.1 mm, N 5 400, P , 0.01). These results show that
somatic delivery of the human tissue kallikrein gene attenuates
cardiac hypertrophy in this model of rats with nephrotoxicity.
Effects of kallikrein gene delivery on kidney morphology
Figure 6 shows the morphology of a kidney stained with
hematoxylin and eosin (H&E) examined with light-microscopy.
The fixation, embedding and staining of non-treated control
animals resulted in well preserved kidney morphology in both the
cortex and medulla (Fig. 6 A, D). Widespread areas of tubular
dilation and damage were observed 10 days in the renal cortex of
rats injected with gentamycin and Ad.CMV-LacZ (Fig. 6 B). Most
proximal tubules were damaged and many were filled with ne-
crotic cells. Distal tubules exhibited less damage and collecting
ducts appeared relatively normal. Cortical renal tubular lumen
were often filled with protein casts. Medullary tubules did not
appear damaged in structure, but protein casts often filled the
lumens, particularly in the outer medulla (Fig. 6 E). In the
kallikrein gene-treated group (Ad.CMV-cHK; Fig. 6 C, F), swell-
ing of proximal tubular cells was seen, but frank cellular necrosis
was rare. Fewer dilated renal tubules were observed after kal-
likrein gene delivery than in the Ad.CMV-LacZ group.
Figure 7 shows the morphology of kidney stained by periodic
acid-Schiff reaction (PAS) for carbohydrates of brush borders and
basement membranes. The morphology of the kidney in control
rats without gentamycin treatment was well preserved in both the
cortex (Fig. 7A) and medulla (data not shown). In the renal cortex
of rats injected with gentamycin and Ad.CMV-LacZ 10 days after
gene delivery, lumenal casts were generally PAS-positive, most
probably derived from sloughed brush border glycoprotein of
damaged proximal tubule cells (Fig. 7B). In the kallikrein gene-
treated group (Ad.CMV-cHK), PAS staining of sections from
these animals often showed intact brush borders on proximal
tubule cells (Fig. 7C). Although protein casts were found in the
outer medulla, they were not as large or as abundant as in the
Ad.CMV-LacZ group. Glomeruli appeared relatively normal in
the Ad.CMV-cHK group.
At 14 days post-injection, renal damage was comparable to that
seen after 10 days of gentamycin treatment but was more wide-
spread in the kidneys of the Ad.CMV-LacZ animals, in which
tubular dilation and necrosis were very extensive (data not
Table 1. Effects of human kallikrein gene delivery on the physiological
parameters in gentamycin nephrotoxic rats
Variables
Groups
Control Gentamycin
Gentamycin
Ad.CMV-LacZ
Gentamycin
Ad.CMV-
cHK
Body wt g 254.1 6 2.8 248.2 6 3.0 247.6 6 2.3 242.7 6 0.8
BP mm Hg 144.2 6 2.0 146.9 6 1.6 141.0 6 3.0 143.8 6 2.9
HR beats/
min
381.6 6 6.3 383.2 6 11.0 372.4 6 7.2 359.5 6 9.2
Urine
volume
7.6 6 1.4 10.4 6 1.8 9.6 6 1.2 11.2 6 1.5
ml/day/
100 g BW
Water
intake
6.1 6 0.8 7.2 6 1.7 7.0 6 1.2 10.7 6 1.8
ml/day/
100 g BW
Urine kinin 24.6 6 5.2 27.5 6 3.0 29.5 6 4.6 87.8 6 21.4a
ng/100 g
BW/day
Urine nitric
oxide
433.5 6 105.5 561.4 6 63.3 666.4 6 74.8 976.9 6 63.4a
mM/100 g
BW/day
Urinary
human
ND ND ND 4.2 6 0.9
kallikrein
mg/100 g
BW/day
Gentamycin-induced nephrotoxicity in rats receiving adenoviral vectors
Ad.CMV-cHK or Ad.CMV-LacZ via the tail vein on the first day of
gentamycin administration. Urine collection was performed 7 days after
gene delivery. Values for each group are reported as mean 6 SEM (N 5 6).
Statistical significance among the three groups were determined by
ANOVA. Abbreviations are: ND, not detected; BW, body weight; BP,
blood pressure; HR, heart rate.
a P , 0.05 vs. gentamycin and Ad.CMV-LacZ group
Table 2. Effects of human kallikrein gene delivery on renal function of
gentamycin nephrotoxic rats
Variables
Groups
Control Gentamycin
Gentamycin
Ad.CMV-LacZ
Gentamycin
Ad.CMV-
cHK
MAP mm Hg 136.0 6 6.8 120.3 6 4.7 124.5 6 16.3 111.3 6 8.5
UF ml/min/g
KW
5.7 6 0.4 4.4 6 0.3 5.0 6 0.2 18.5 6 0.4a
GFR ml/min/g
KW
0.94 6 0.06 0.73 6 0.05 0.83 6 0.04 3.07 6 0.07a
RBF ml/min/g
KW
11.1 6 0.9 8.7 6 0.8 9.2 6 0.6 32.0 6 2.1a
Kidney weight
g/100 g BW
0.74 6 0.04 1.19 6 0.14b 1.05 6 0.08b 1.05 6 0.05b
Body weight g 285.4 6 4.5 233.1 6 10.8b 237.8 6 3.5b 222.3 6 1.9b
Hematocrit % 59.7 6 1.6 59.7 6 2.7 57.0 6 2.5 54.0 6 1.9
Gentamycin-induced nephrotoxicity in rats receiving adenoviral vectors
Ad.CMV-cHK or Ad.CMV-LacZ via the tail vein on the first day of
gentamycin administration. Renal function study was performed and
kidney weights were measured at 10 days after gene delivery. Abbrevia-
tions are: MAP, mean arterial pressure; UF, urine flow; GFR, glomerular
filtration rate; RBF, renal blood flow; KW, kidney weight; BW, body
weight. Values for each group are reported as mean 6 SEM (N 5 4).
Statistical significance among the four groups were determined by
ANOVA.
a P , 0.01 vs. gentamycin and Ad.CMV-LacZ group
b P , 0.01 vs. control group
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shown). Indeed, few normal proximal tubules were observed and
many protein casts were present in the outer medulla. By contrast,
kidneys of animals of the kallikrein gene-treated group exhibited
morphological indications of recovery. Renal tubular damage was
not as severe as the damage seen in the Ad.CMV-LacZ group.
Enlarged nuclei and mitoses were often observed in renal tubular
cells, suggesting the likelihood of renal tubular regeneration. Few
protein casts were present in the medulla. In all cases, despite the
obvious tubular damage in all animals treated with gentamycin,
the renal corpuscles (glomeruli and Bowman’s capsule) exhibited
little histological evidence of damage when stained with H&E.
DISCUSSION
In this study, we showed that adenovirus-mediated delivery of
the human tissue kallikrein gene via intravenous injection dis-
played protective effects on gentamycin-induced nephrotoxicity in
rats. High levels of recombinant human tissue kallikrein were
found in the rat bloodstream and urine in a time-dependent
manner following injection of the adenovirus carrying the human
tissue kallikrein gene. Kallikrein gene delivery significantly atten-
uated proximal tubular damage; there was a loss of brush border
as well as frank cellular necrosis, and a reduction of protein casts
of the lumens of medullary tubules. In addition, kallikrein gene
delivery also enhanced renal function and inhibited cardiac hy-
pertrophy. The expression of human tissue kallikrein mRNA was
identified in tissues relevant to cardiavascular and renal function
such as the kidney, aorta and heart. These findings suggest the
potential of applying kallikrein gene therapy approaches to treat
drug-induced renal and/or cardiovascular diseases.
The mechanisms of gentamycin-induced nephrotoxicity has
been investigated in previous studies [22, 23]. Gentamycin is
filtered through the glomerular basement membranes and is taken
up via pinocytosis into proximal tubular cells [24]. Renal injury
from aminoglycoside administration results from accumulation of
this drug in proximal tubules and interference with cellular
energetics [23]. Gentamycin treatment has been shown to reduce
both phospholipase and sphingomyelinase activities in the kidney
and inhibit phospholipid metabolism [9–12]. Therefore, renal
cortical phospholipidosis may be one of the potential mechanisms
of gentamycin-induced nephrotoxicity. Orfila et al [25] reported
that cisplatin administration induced proximal tubular cell injury
as well as decreased urinary kallikrein levels. Therefore, the
measurement of urinary kallikrein excretion can serve as an index
of tubular damage during exposure to heavy metals such as
mercuric chloride [26], molybdenum [27] and cadmium [28].
Consistent with these studies, we found that urinary excretion of
endogenous tissue kallikrein is significantly suppressed in rats
treated with gentamycin (data not shown). In addition, our recent
studies showed that adenovirus-mediated gene delivery of human
tissue kallikrein alleviated renal damage in Dahl-salt sensitive rats
fed a high salt diet [14]. Together, these findings suggest that a
continuous supply of tissue kallikrein has protective effects
against renal injury. The present study demonstrated that systemic
delivery of the human tissue kallikrein gene could attenuate renal
damage induced by gentamycin.
In addition to the morphological changes, significant increases
in urine flow, GFR and RBF as well as a significant decrease in
elevation of blood urea nitrogen levels were observed in genta-
mycin-treated rats after kallikrein gene delivery. These results
showed that systemic delivery of the human tissue kallikrein gene
had protective effects on renal function in this rat model of acute
Fig. 5. Left ventricular weight (A) and cardiomyocyte diameter (B) of
gentamycin nephrotoxicity rats after adenovirus-mediated kallikrein gene
delivery. Data are expressed as mean 6 SEM (N 5 4). *P , 0.01 versus the
gentamycin and Ad.CMV-LacZ group.
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Fig. 6. Histological sections of kidney cortex (A, B, C) and medulla (D, E,
F), stained with hematoxylin and eosin. (A and D.) Control, Sprague-
Dawley rat, given saline. The cortex (A) and medulla (D) generally appear
normal. (B and E.) Sprague-Dawley rat, injected with gentamycin daily for
10 days, receiving control adenovirus, Ad.CMV-LacZ. Note the cortical
tubular damage (B) and colloidal casts in the medulla (E). (C and F.)
Sprague-Dawley rat, injected with gentamycin daily for 10 days, receiving
Ad.CMV-cHK, the human tissue kallikrein gene construct. Note de-
creased proximal tubular dilation and damage with few tubular casts
compared with sections from the rat receiving Ad.CMV-LacZ (C vs. B; F
vs. E) (Magnification A, B and C, 3200; D, E, F, 3100).
Fig. 7. Histological sections of kidney cortex stained with periodic acid-
Schiff (PAS). (A) Control, Sprague-Dawley rat, injected with saline. The
PAS-positive brush border and glomerular basement membrane of the
cortex appear normal. (B) Sprague-Dawley rat, injected with gentamycin,
receiving control adenovirus, Ad.CMV-LacZ. Note glomeruli with thick-
ened, PAS-positive basement membrane and damaged proximal tubules
lacking obvious brush border. (C) Sprague-Dawley rat, injected with
gentamycin, receiving Ad.CMV-cHK, the human kallikrein gene con-
struct. Note less thickened glomerular basement membranes and less
dilated proximal tubules, some with intact brush borders compared with
animals receiving the LacZ gene (C vs. B) (magnification 3200).
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renal failure. These findings are consistent with our recent studies
that kallikrein gene delivery enhanced renal function in two-
kidney, one-clip Goldblatt hypertensive rats with renovascular
hypertension [15]. In addition, urinary kinin and nitrite/nitrate
levels increased markedly after kallikrein gene delivery. These
results indicate a dramatic increase in intrarenal kinin levels in the
rats after kallikrein gene transfer. These findings suggest that
increased renal function following kallikrein gene delivery was
mediated by increased kinin levels. This notion is supported by a
previous study employing bradykinin antagonists suggesting that
endogenous kinins contribute to the regulation of renal blood flow
in the kidney [21]. In addition, it is well known that kinins activate
phospholipase A and prevent phospholipidosis in renal tubules
and that kinins also enhance renal function. These might be
attributed, in part, to reducing gentamycin accumulation in renal
proximal tubules. Also, kallikrein is a nonspecific serine protein-
ase and can cleave many protein substrates including pre-
proEGF. Epidermal growth factor (EGF) is a well known growth
factor that could accelerate renal tissue repair in rats experiencing
gentamycin nephrotoxicity [29]. These are possible mechanisms of
protecting against renal damage by kallikrein gene delivery.
The mechanisms of increased renal function following kal-
likrein gene delivery appear to be mediated via kinin through a
nitric oxide signal transduction pathway. It is well known that
bradykinin can produce vasodilatory and natriuretic effects when
infused into the renal artery [30]. In addition, various kininase
inhibitors are able to increase urinary kinins, sodium and water
excretion [31], and papillary blood flow [32]. In this study, we
showed that adenovirus-mediated gene delivery results in the
expression of human tissue kallikrein in rat kidney. However,
cellular localization of human tissue kallikrein and its mRNA in
rat kidney has yet to be identified. Expression of recombinant
human tissue kallikrein in the kidney could lead to increased kinin
formation in the urine of rats receiving the kallikrein gene.
Therefore, binding of kinins to the bradykinin B2 receptor triggers
the activation of a second messenger such as NO. The influence of
other potential second messengers such as cGMP or eicosanoids
in triggering kinin’s effects on blood pressure remains to be
elucidated.
The present study shows that rats with gentamycin-induced
nephrotoxicity exhibit structural changes within the heart. Left
ventricular hypertrophy has been demonstrated within 10 days
following gentamycin administration. These structural alterations
are an important factor in the maintenance of the elevated
peripheral resistance caused by acute renal failure in this neph-
rotoxicity model. A previous report described that gentamycin-
mediated acute renal failure in rats was accompanied by the
activation of the renin-angiotensin system [33]. Although our
study did not show an association with systemic hypertension in
gentamycin nephrotoxic rats, the activated renin-angiotensin sys-
tem might stimulate cardiomyocytes directly or indirectly by
volume retention to cause cardiac hypertrophy. A nondepressor
dose of an ACE inhibitor has been shown to prevent the
development of cardiac hypertrophy in renal hypertension [34],
and this protective effect was abolished by bradykinin B2 receptor
antagonist [35]. Kinin accumulation resulting from kallikrein gene
delivery may contribute significantly to prevention of cardiac
hypertrophy in rats with nephrotoxicity. Although the expression
level of human tissue kallikrein mRNA in the heart of the rats
following gene delivery was low, high levels of human kallikrein
were detected in the bloodstream. Therefore, circulating and/or
local tissue kallikrein/kinin might play a role in preventing cardiac
hypertrophy in rats following kallikrein gene delivery.
In our study, blood pressure caused no significant changes
among the group during the study. Our previous report showed
that kallikrein gene delivery had hypotensive effects in spontane-
ously hypertensive rats (SHR) but not in normotensive Wistar-
Kyoto (WKY) rats [36]. Since urinary kinin and human tissue
kallikrein levels in sera and urine of WKY rats were similar to
those of SHR following kallikrein gene delivery, the differential
effects of gene delivery on blood pressure might be attributed to
their different sensitivities to the exogenous kallikrein in the
vasculature. On the other hand, enhanced renal function in
Sprague-Dawley rats injected with Ad.CMV-cHK might cause
higher cardiac output than the control rats, the reason for the
normotensive state might be a reduction of peripheral resistance
by the vasodilative effect of kinin. The mechanism for this observa-
tion is not clear at the present time. Although we did not measure
plasma renin activity in this study, the renin-angiotensin system
might be activated to compensate for the blood pressure effect.
As for body weight, significant differences were found between
seven and 10 days in the gentamycin-administered groups after
gene delivery. There were no significant differences in body
weight among the four groups at day 7, however, body weight of
rats receiving gentamycin was significantly lower than that of
control groups injected with saline alone at day 10. The body
weight loss might have been caused by reduced appetite as a result
of gentamycin-induced nephrotoxicity. We found that hematocrit
levels were similar among different groups of rats. Therefore,
reduced water intake should not account for the weight loss.
Despite the obvious histologic evidence of tubular damage,
RBF and GFR were not decreased in gentamycin-treated animals.
On the other hand, BUN was markedly elevated (up to 4 times
normal). Blood urea nitrogen can be affected by protein intake,
protein catabolic rate and the state of hydration. However, we
found no significant difference in hematocrit data among the four
groups. Therefore, the effect of hydration can be excluded.
Although we did not analyze food consumption of these rats,
appetite loss and changes in protein catabolic rate as a result of
renal failure might be attributed to BUN elevation. We observed
severe necrosis in proximal tubules histopathologically with no
significant decrease in renal function after gentamycin adminis-
tration. A previous report described that a decrease in GFR is a
relatively late manifestation of aminoglycoside nephrotoxicity
[37]. Decreased urine concentrating capacity, proteinuria, en-
zymuria, and alternations of proximal tubule organic acid trans-
port are characteristically seen before there is any significant
depression of GFR. In addition, histopathologic lesions of focal
proximal tubular cell necrosis may be present in the absence of
any depression of whole kidney GFR. Since we evaluated renal
function 10 days after gentamycin treatment, we could not find a
significant decrease in renal function compared to the control
group injected with saline.
We observed that human tissue kallikrein levels in the serum of
gentamycin nephrotic rats reached its peak at three days after
kallikrein gene delivery and declined gradually. Similar serum
profiles of human tissue kallikrein levels were also detected after
kallikrein gene delivery in spontaneously hypertensive and in
Dahl-salt sensitive hypertensive rats in our laboratory [14, 36]. A
decline of human kallikrein levels after kallikrein gene delivery
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might be due to immunogenicity and inactivation or clearance of
the adenovirus.
In conclusion, adenovirus-mediated human tissue kallikrein
gene delivery has protective effects on nephrotoxicity and cardiac
hypertrophy in rats with gentamycin administration. Although
gentamycin-induced nephrotoxicity can be treated with drugs or
dietary supplements such as fish oil or calcium [22], these treat-
ments require daily administration. This study shows that kal-
likrein gene delivery could attenuate renal injury as well as
enhance renal function. Further technical improvements in deliv-
ery methodologies may lead to future clinical application of gene
therapy in treating drug-induced renal diseases.
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